Capecitabine-induced cardiotoxicity: more evidence or clinical approaches to protect the patients’ heart?
Fontanella C, Aita M, Cinausero M, Aprile G, Baldin MG, Dusi V, Lestuzzi C, Fasola G, Puglisi F.
Onco Targets Ther. 2014 Sep 29;7:1783-91. doi: 10.2147/OTT.S65653. eCollection 2014.
CARDIONCOLOGY.ORG ABSTRACT:
Cardiac toxicity as a side effect of treatment with fluoropyrimidines, such as capecitabine and 5-fluorouracil, has increased and is expected to rise due to the disproportionate incidence of breast and gastrointestinal cancers in older individuals.
This article discusses the case of a 43-year-old woman with advanced breast cancer in relation to the differential diagnosis of capecitabine-related cardiac toxicity, its risk factors, and the underpinning mechanisms of early onset.
© All rights reserved
image source: http://www.revistadelaofil.org/wp-content/uploads/2016/09/Capecitabina-formulaci%C3%B3n-innovadora-y-gen%C3%A9rica-perfil-de-seguridad.jpg